The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
Open accessAbstract
Canagliflozin reduced kidney disease progression in participants with type 2 diabetes in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. This analysis explored potential mediators of the effects of canagliflozin on kidney outcomes. The percent mediating effect of 18 biomarkers indicative of disease was determined by comparing the hazard ratios for the effect of randomized treatment from an unadjusted model and from a model adjusting for the average post-randomization level of each biomarker. Multivariable analyses assessed the joint effects of biomarkers that mediated most strongly in univariable analyses. The kidney outcome was defined as a composite of 40% estimated glomerular filtration rate decline, end-stage kidney disease, or death due to kidney disease. Nine biomarkers (systolic blood pressure [8.9% of effect explained], urinary albumin:creatinine ratio [UACR; 23.9%], gamma glutamyltransferase [4.1%], hematocrit [51.1%], hemoglobin [41.3%], serum albumin [19.5%], erythrocytes [56.7%], serum urate [35.4%], and urine pH [7.5%]) individually mediated the effect of canagliflozin on the kidney outcome. In a parsimonious multivariable model, erythrocyte concentration, serum urate, and systolic blood pressure maximized cumulative mediation (115%). Mediating effects of UACR, but not other mediators, were highly dependent upon the baseline level of UACR: UACR mediated 42% and 7% of the effect in those with baseline UACR 30 mg/g or more and under 30 mg/g, respectively. The identified mediators support existing hypothesized mechanisms for the prevention of kidney outcomes with sodium glucose co-transporter 2 inhibitors. Thus, the disparity in mediating effects across baseline UACR subgroups suggests that the mechanism for kidney protection with canagliflozin may vary across patient subgroups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Reduction in albuminuria is also important to evaluate the efficacy of medications prescribed for kidney protection, as both SGLT2 inhibitors and finerenone have shown that the majority of their beneficial effect is mediated by reduction in albuminuria (42,43).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [43]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationMacKinnon, D. P., Fairchild, A. J., & Fritz, M. S. (2007) · Annual Review of Psychology · doi:10.1146/annurev.psych.58.110405.085542 · Cited by 5,688
Introduction to Statistical Mediation Analysis
MacKinnon, D. P. (2012) · doi:10.4324/9780203809556 · Cited by 5,618
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 1×
“T he CANagliflozin cardioVascular Assessment Study (CANVAS) Program reported that the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduces the risk of clinically important kidney outcomes in patients with type 2 diabetes with established cardiovascular disease or those at high cardiovascular risk.(1)…”
BackgroundSurrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationPathophysiology of Progressive Nephropathies
Remuzzi, G., & Bertani, T. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811123392007 · Cited by 1,258
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Cited by
Sorted by citations
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 556
Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes
Agarwal, R., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Rosenstock, J., Rossing, P., Vaduganathan, M., Brinker, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410659 · Cited by 319
Self-citationZannad, F. M., Ferreira, J. P., Butler, J., Filippatos, G. S., Januzzi, J. L., Sumin, M., Zwick, M., Saadati, M., Pocock, S., Sattar, N. A., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac495 · Cited by 202
Apperloo, E. M., Neuen, B. L., Fletcher, R. A., Jongs, N., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Herrington, W. G., Inzucchi, S. E., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00155-4 · Cited by 180
Self-citationA kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
Sen, T., & Heerspink, H. J. L. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.02.016 · Cited by 161
Self-citationIron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
Docherty, K. F., Welsh, P. I., Verma, S., de Boer, R. A., O’Meara, E., Bengtsson, O., Køber, L., Kosiborod, M., Hammarstedt, A., Langkilde, A. M., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.060511 · Cited by 154
Ku, E., Vecchio, L. D., Eckardt, K., Haase, V. H., Johansen, K. L., Nangaku, M., Tangri, N., Waikar, S. S., Więcek, A., Cheung, M., et al. (2023) · Kidney International · doi:10.1016/j.kint.2023.05.009 · Cited by 162
Oshima, M., Neuen, B. L., Jardine, M. J., Bakris, G., Edwards, R., Levin, A., Mahaffey, K. W., Neal, B., Pollock, C., Rosenthal, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30300-4 · Cited by 135
Self-citationPotential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
Mann, J. F. E., Buse, J. B., Idorn, T., Leiter, L. A., Pratley, R. E., Rasmussen, S., Vilsbøll, T., Wolthers, B., & Perkovic, V. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14443 · Cited by 120
Self-citationSGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function
Suijk, D. L. S., van Baar, M. J. B., van Bommel, E. J. M., Iqbal, Z., Krebber, M. M., Vallon, V., Touw, D. J., Hoorn, E. J., Nieuwdorp, M., Kramer, M. M. H., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11480821 · Cited by 111
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 108
Badura, K., Janc, J. J., Wąsik, J., Gnitecki, S., Skwira, S., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · Biomedicines · doi:10.3390/biomedicines12061191 · Cited by 106
State-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications
Vallon, V. (2024) · American Journal of Hypertension · doi:10.1093/ajh/hpae092 · Cited by 119
Staplin, N., Haynes, R., Judge, P., Wanner, C., Green, J., Emberson, J., Preiss, D., Mayne, K., Ng, S., Sammons, E. L., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00321-2 · Cited by 102
Self-citationRavindran, S., & Munusamy, S. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30621 · Cited by 98
Sen, T., Li, J., Neuen, B. L., Neal, B. C., Arnott, C. G., Parikh, C. R., Coca, S. G., Perkovic, V., Mahaffey, K. W., Yavin, Y., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05512-5 · Cited by 94
Self-citationHyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure
Packer, M. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.030 · Cited by 80
Persson, F., Rossing, P., Vart, P., Chertow, G. M., Hou, F. F., Jongs, N., McMurray, J. J. V., Correa-Rotter, R., Bajaj, H. S., Stefansson, B. V., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0300 · Cited by 78
Self-citationFrom Proteinuria to Fibrosis: An Update on Pathophysiology and Treatment Options
Sharma, S., & Smyth, B. J. (2021) · Kidney & Blood Pressure Research · doi:10.1159/000516911 · Cited by 73
How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial
Wanner, C., Nangaku, M., Kraus, B. J., Zinman, B., Mattheus, M., Hantel, S., Schumacher, M. C., Ohneberg, K., Schmoor, C., & Inzucchi, S. E. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae032 · Cited by 54
Guedes, M. H., & Pecoits‐Filho, R. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13424 · Cited by 53
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 54
Tian, Q., Guo, K., Deng, J., Zhong, Y., & Yang, L. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17115 · Cited by 51
Segar, M. W., Kolkailah, A. A., Frederich, R. C., Pong, A., Cannon, C. P., Cosentino, F., Dagogo-Jack, S. E., McGuire, D. K., Pratley, R. E., Liu, C., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14769 · Cited by 43
Aroda, V. R., & Eckel, R. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14830 · Cited by 40
Koshino, A., Neuen, B. L., Jongs, N., Pollock, C. A., Greasley, P. J., Andersson, E.-M., Hammarstedt, A., Karlsson, C., Langkilde, A. M., Wada, T., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02027-8 · Cited by 40
Self-citationSen, T., Li, J., Neuen, B. L., Arnott, C. G., Neal, B., Perkovic, V., Mahaffey, K. W., Shaw, W., Canovatchel, W., Hansen, M. K., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021661 · Cited by 35
Self-citationVallon, V. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae060 · Cited by 37
Girardi, A. C. C., Polidoro, J. Z., Castro, P. C., Pio-Abreu, A., Noronha, I. L., & Drager, L. F. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00143.2024 · Cited by 32
Natale, P., Tunnicliffe, D. J., Toyama, T., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Gargano, L., Stallone, G., Gesualdo, L., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015588.pub2 · Cited by 36
A meta-analysis of albuminuria as a surrogate endpoint for kidney failure
Heerspink, H. J. L., Collier, W., Chaudhari, J., Miao, S., Tighiouart, H., Appel, G. B., Caravaca‐Fontán, F., Floege, J., Hannedouche, T. P., Imai, E., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04057-z · Cited by 31
Self-citationHare, G. M. T., Zhang, Y., Chin, K., Thai, K., Jacobs, E., Cazorla‐Bak, M. P., Nghiem, L., Wilson, D. F., Vinogradov, S. A., Connelly, K. A., et al. (2021) · Physiological Reports · doi:10.14814/phy2.14890 · Cited by 31
Agarwal, R., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Rosenstock, J., Rossing, P. R., Vaduganathan, M., BRINKER, M. D., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf022 · Cited by 32
Self-citationSen, T., Koshino, A., Neal, B. C., Bijlsma, M. J., Arnott, C. G., Li, J., Hansen, M. K., Ix, J. H., & Heerspink, H. J. L. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14779 · Cited by 29
Self-citationRenal Tubular Handling of Glucose and Fructose in Health and Disease
Vallon, V., & Nakagawa, T. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210030 · Cited by 49
Sridhar, V. S., Limonte, C. P., Groop, P., Heerspink, H. J. L., Pratley, R. E., Rossing, P. R., Skyler, J. S., & Cherney, D. Z. I. (2023) · Diabetologia · doi:10.1007/s00125-023-06015-1 · Cited by 33
Self-citationAssociation between urinary uric acid excretion and kidney outcome in patients with CKD
Asahina, Y., Sakaguchi, Y., Oka, T., Hattori, K., Kawaoka, T., Doi, Y., Yamamoto, R., Matsui, I., Mizui, M., Kaimori, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-55809-9 · Cited by 27
Mayne, K. J., Sardell, R. J., Staplin, N., Judge, P. K., Zhu, D., Sammons, E. L., Cherney, D. Z. I., Green, J. B., Levin, A., Pontremoli, R., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae203 · Cited by 30
Self-citationThe Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1
Oe, Y., & Vallon, V. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2020032 · Cited by 29
Renoprotective Effects of SGLT2 Inhibitors
Vallon, V. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.005 · Cited by 27
Gohda, T., & Murakoshi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213749 · Cited by 28
McCormick, N., Yokose, C., Lu, N., Wexler, D. J., Aviña-Zubieta, J. A., Vera, M. A. D., Chigurupati, S., Tan, K., Chen, C., McCoy, R. G., et al. (2024) · BMJ · doi:10.1136/bmj-2024-080035 · Cited by 24
Sinha, F., Federlein, A., Biesold, A., Schwarzfischer, M., Krieger, K., Schweda, F., & Tauber, P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1118358 · Cited by 23
Cardiorenal Protection in Diabetic Kidney Disease
Lee, J. F., Berzan, E., Sridhar, V. S., Odutayo, A., & Cherney, D. Z. I. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.987 · Cited by 21
Rodriguez‐Valadez, J. M., Tahsin, M., Masharani, U. B., Park, M., Hunink, M. G. M., Yeboah, J., Li, L., Weber, E. S., Berkalieva, A., Avezaat, L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032463 · Cited by 21
Sodium–glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria
Delanaye, P., Wissing, K. M., & Scheen, A. J. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab096 · Cited by 21
SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes
Wu, Q., Zhang, J., Zhang, F., & Li, D. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1601633 · Cited by 20
Scheen, A. J., & Delanaye, P. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2014322 · Cited by 18
Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females
Doi, Y., Hamano, T., Yamaguchi, O., & Isaka, Y. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016320 · Cited by 20
Dapagliflozin for the treatment of chronic kidney disease
Kurata, Y., & Nangaku, M. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2099373 · Cited by 19
Ferrannini, E., Solini, A., Baldi, S., Scozzaro, T., Polidori, D., Natali, A., & Hansen, M. K. (2023) · Diabetes · doi:10.2337/db23-0448 · Cited by 18
Sridhar, V. S., Heerspink, H. J. L., Davies, M. J., Banks, P. L., Girard, M., Garg, S. K., & Cherney, D. Z. I. (2023) · Diabetes Care · doi:10.2337/dc23-0129 · Cited by 17
Self-citationShenoy, S. V., Nagaraju, S. P., Bhojaraja, M. V., Prabhu, R., Rangaswamy, D., & Rao, I. R. (2021) · Nephrology · doi:10.1111/nep.13917 · Cited by 16
Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease
Tiku, A., Johnson, D. W., & Badve, S. V. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000699 · Cited by 15
Sridhar, V. S., Ambinathan, J. P. N., Gillard, P., Mathieu, C., Cherney, D. Z. I., Lytvyn, Y., & Singh, S. K. (2021) · Transplantation · doi:10.1097/tp.0000000000003919 · Cited by 15
Liu, H., Sridhar, V. S., Perkins, B. A., Rosenstock, J., & Cherney, D. Z. I. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01471-2 · Cited by 14
Cases, A., Cigarrán, S., Górriz, J. L., & Núñez, J. E. (2023) · Nefrología · doi:10.1016/j.nefro.2023.11.001 · Cited by 14
Effect of SGLT2 inhibitors on anemia and their possible clinical implications
Cases, A., Cigarrán, S., Górriz, J. L., & Núñez, J. E. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.03.011 · Cited by 15
Heerspink, H. J. L., Stack, A. G., Terkeltaub, R. A., Greene, T., Inker, L. A., Bjursell, M. K., Perl, S., Rikte, T., Erlandsson, F., & Perkovic, V. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab237 · Cited by 13
Self-citationDoi, Y., Hamano, T., Yamaguchi, S., Sakaguchi, Y., Kaimori, J., & Isaka, Y. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15191 · Cited by 13
Budoff, M. J., Davis, T. M. E., Palmer, A. G., Frederich, R. C., Lawrence, D. E., Liu, J., Gantz, I., & Derosa, G. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01033-x · Cited by 13
Tye, S. C., de Vries, S. T., Wanner, C., Denig, P., & Heerspink, H. J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.786706 · Cited by 12
Self-citationLi, J., Arnott, C. G., Heerspink, H. J. L., MBiostat, Q. L., Cannon, C. P., Wheeler, D. C., Charytan, D. M., Barraclough, J., Figtree, G. A., Agarwal, R., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.025045 · Cited by 11
Self-citationSGLT2i in Patients with Type 1 Diabetes: Benefits, Risks, and Preventive Strategies
Ma, Y., Zhao, Q., Peng, H., Nalisa, D. L., Shan, P., & Jiang, H. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2805098 · Cited by 11
Innovative therapeutics for renoprotection: Where we are
Cortinovis, M., Perico, N., & Remuzzi, G. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100060 · Cited by 10
Schwarz, Y., Klein, P., & Lev-Shalem, L. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02174-0 · Cited by 9
Bishr, A., El-Mokadem, B. M., & Gomaa, A. A. (2025) · Scientific Reports · doi:10.1038/s41598-024-82163-7 · Cited by 9
Wen, S., Yuan, Y., Li, Y., Xu, C., Chen, L., Ren, Y., Wang, C., He, Y., Li, X., Gong, M., et al. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01985-2 · Cited by 13
The future of Diabetic Kidney Disease management: reducing the unmet need
de Zeeuw, D. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00820-2 · Cited by 9
Pollock, C. A., & Neuen, B. L. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.02.006 · Cited by 10
Self-citationLiver function markers predict cardiovascular and renal outcomes in the CANVAS Program
Ferrannini, G., Rosenthal, N. R., Hansen, M. K., & Ferrannini, E. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01558-w · Cited by 9
Sridhar, V. S., Cosentino, F., Dagogo-Jack, S. E., McGuire, D. K., Pratley, R. E., Cater, N. B., Essex, M. N., Mancuso, J. P., Zhao, Y., & Cherney, D. Z. I. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15895 · Cited by 9
van Mil, D., Kieneker, L. M., Harms, E., Prins, G. H., van Geer-Postmus, I., Mepschen, M., Leving, M. T., Stoker, N., Kocks, J. W. H., Gansevoort, R. T., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103185 · Cited by 9
Self-citationBonnet, F., Vaduva, P., Halimi, J., Dosda, A., Ducluzeau, P., Koppe, L., & Fauchier, L. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02930-2 · Cited by 9
Speedtsberg, E. S., & Tepel, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1281107 · Cited by 9
Yang, H., Yang, L., Jardine, M., Arnott, C. G., Neuen, B. L., Xu, K., Zhao, X., Qian, D., Cui, B., Qiu, Y., et al. (2024) · European journal of medical research · doi:10.1186/s40001-024-02214-7 · Cited by 8
Self-citationCardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes
Nazari, S., & Mirkhani, H. (2022) · Current Diabetes Reviews · doi:10.2174/1573399819666221222160035 · Cited by 8
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
Charytan, D. M., Mahaffey, K. W., Jardine, M., Cannon, C. P., Neal, B. C., Heerspink, H. J. L., Agarwal, R., Bakris, G. L., de Zeeuw, D., Levin, A., et al. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003270 · Cited by 10
Self-citationTesfaye, H., Wang, K. M., Zabotka, L. E., Wexler, D. J., Schmedt, N., Koeneman, L., SEMAN, L. J., Paik, J. M., & Patorno, E. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08793-9 · Cited by 7
Chen, A., Fletcher, R., Neuen, B. L., Neal, B. C., & Arnott, C. G. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15751 · Cited by 8
Self-citationMatsubayashi, Y., Yoshida, A., Suganami, H., Oe, M., Sato, T., Yaguchi, Y., Fujihara, K., Yamada, T., Tanaka, S., Kaku, K., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14836 · Cited by 7
Kidney involvement in glycogen storage disease type I: Current knowledge and key challenges
Schumann, A., Garbade, S. F., Beblo, S., Gautschi, M., Haas, D., Hochuli, M., Hoffmann, G. F., May, P., Merkel, M., Scholl‐Bürgi, S., et al. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109054 · Cited by 6
Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure
Lytvyn, Y., Scholtes, R. A., Boorsma, E. M., Sridhar, V. S., Kugathasan, L., Liu, H., Lovblom, L. E., Handoko, M. L., Mosterd, C. M., Floras, J. S., et al. (2025) · Physiological Reports · doi:10.14814/phy2.70275 · Cited by 6
Self-citationZheng, T., Luo, L., Wang, X., Deng, X., & Xue, M. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112038 · Cited by 8
Shi, Y., Dong, S., Xu, Y., Ji, D., Yang, L., & Zhao, R. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02252-x · Cited by 6
Effects of antidiabetic drugs on the level of serum uric acid in patients who have type 2 diabetes
Wang, G., & Wang, G. (2025) · Saudi Medical Journal · doi:10.15537/smj.2025.46.3.20240920 · Cited by 6
Patoulias, D., Eid, A. H., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108630 · Cited by 6
Berezin, A. Е., & Berezina, T. A. (2024) · Journal of International Medical Research · doi:10.1177/03000605241227659 · Cited by 6
Goodluck, H., Zemljic‐Harpf, A. E., Galdino, O. A., Kanoo, S., Lopez, N., Kim, Y., & Vallon, V. (2025) · Physiological Reports · doi:10.14814/phy2.70217 · Cited by 5
Weingold, R., Zinman, B., Mattheus, M., Ofstad, A. P., Steubl, D., Wanner, C., & Inzucchi, S. E. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108628 · Cited by 5
Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
Portalatin, G. M., Hong‐McAtee, I., Burgner, A. M., Gould, E. R., & Hunley, T. E. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1521425 · Cited by 7
Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease
Gan, T., Song, Y., Guo, F., & Qin, G. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07758-7 · Cited by 4
Georgianos, P. I., Koufakis, T., Arampatzis, S., & Liakopoulos, V. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70026 · Cited by 3
Chalès, G., Coiffier, G., & Robin, F. (2025) · EMC - Appareil locomoteur · doi:10.1016/s0246-0521(25)47868-1 · Cited by 3
Sridhar, V. S., Kugathasan, L., Lytvyn, Y., Deng, Y., Liu, H., Lovblom, L. E., TSE, J. M., Nardone, M., Floras, J. S., Osuntokun, T., et al. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25955 · Cited by 3
Self-citationMaruhashi, T., Tanaka, A., Takahashi, K., Higashi, Y., Node, K., & the PROCEED trial investigators (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15481 · Cited by 3
Steinmetz, T., Goldman, S. N., Kagan, K. B. T., Bielopolski, D., Buchrits, S., Schechter, A., Kushnir, S., Turjeman, ., Agur, T., Grossman, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf184 · Cited by 3
Zheng, Q., Yan, Y., Xu, L., Lin, J., Shu, Z., Yan, D., Li, X., Liu, B., Chan, K. W., Fan, G., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157225 · Cited by 3
Sukhareva, O. Y., Zuraeva, Z. T., & Shamhalova, M. (2022) · Diabetes Mellitus · doi:10.14341/dm12864 · Cited by 4
Metadata
- Authors
- Li, J., Neal, B., Perkovic, V., de Zeeuw, D., Neuen, B. L., Arnott, C., Simpson, R., Oh, R., Mahaffey, K. W., & Heerspink, H. J. L.
- Affiliations
- Army Medical University (CN)
- The George Institute for Global Health (GB)
- UNSW Sydney (AU)
- University Medical Center Groningen (NL)
- Royal Prince Alfred Hospital (AU)
- Janssen Research & Development (United States) (US)
- Stanford Medicine (US)
- Corresponding author
- Heerspink, Hiddo J.L.
- ORCID
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 98
- Issue
- 3
- Pages
- 769-777
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W3029576443
- Cited by
- 130
- References
- 41
- Citations by year
- 2026: 8 · 2025: 30 · 2024: 25 · 2023: 21 · 2022: 22 · 2021: 21 · 2020: 3
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Kidney International (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- Janssen Research & Development
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- canagliflozin, type 2 diabetes, renal protection, kidney disease progression, SGLT2 inhibitors, mediation analysis, urinary albumin-creatinine ratio, erythrocyte concentration, serum uric acid, systolic blood pressure, estimated glomerular filtration rate decline, end-stage renal disease, CANVAS trial
- MeSH terms
- Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Humans, Kidney
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
